UCB announces strategic investment in IMIDomics, Inc to advance breakthrough solutions for immune-mediated inflammatory diseases

Brussels (Belgium), and San Rafeal, CA (US), 4^th March, 2024 (18:00 CET) – UCB (Euronext, Brussels: UCB), a global biopharmaceutical company, today announced a strategic equity investment in IMIDomics, Inc, a private company dedicated to the advancement of novel medicines for immune-mediated inflammatory diseases (IMIDs).

“I am extremely enthusiastic about our investment in IMIDomics. Their innovative approach aligns perfectly with our mission to make a meaningful impact on the lives of patients with severe immune-mediated inflammatory diseases,” said Dhaval Patel, Executive Vice President and Chief Scientific Officer at UCB. He continued, "This investment represents more than just financial support. It underscores our belief in IMIDomics' potential and our commitment to fostering their pioneering efforts in the field of immune-mediated inflammatory diseases. We see this as an opportunity to contribute to enhancing patient care standards, and to collaboratively support the progression of medical innovation.”

The parties are also in discussions for a planned research collaboration to leverage the respective expertise, technologies and assets of both companies to accelerate the development of targeted therapies and diagnostic tools for IMIDs and maximize the indications against which new therapies may be used.

"This strategic investment from UCB is a direct result of our successes in developing the deepest understanding of IMID patients through our Clinical Discovery Engine™, which is based on comprehensive, proprietary patient data and human-centered translation,” said Fred Craves, CEO of IMIDomics. “We are enthusiastic about the prospect of collaborating with UCB, a company renowned for its commitment to transforming IMID patient outcomes. Together, we look forward to advancing novel solutions that address the unmet needs of patients suffering from these challenging conditions."

Further financial details of the agreement were not disclosed.

For further information

UCB

R&D Communications - Scott Fleming;
Scott.fleming@ucb.com / T +44 7702777378

Corporate Communications, Media Relations - Laurent Schots
laurent.schots@ucb.com / T +3225599264 

Investor Relations - Antje Witte
antje.witte@ucb.com / T +3225599414

IMIDomics

Shani Lewis - slewis@realchemistry.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8,700 people in approximately 40 countries, the company generated revenue of €5.5 billion in 2022 UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news.

About IMIDomics

IMIDomics has established itself as a leader in the use of deep, multidimensional patient data to generate insights into complex diseases, an approach that is set to dictate the future of precision IMID therapeutics. Its Clinical Discovery EngineTM is built on the foundation of the IMID Investigator Consortium led by Dr. Sara Marsal, Co-founder and Chief Medical Officer of IMIDomics, at the Vall d’Hebron Research Institute in Spain, which has generated comprehensive patient data under a single unified protocol that ensures the quality of the data collected, relevance to disease, and precise alignment of phenotypic and biomolecular data. These data allow the identification of targets underpinning disease phenotypes and the identification of those patients who are most likely to respond to new medicines, improving the therapy for patients while streamlining the drug development process. IMIDomics has identified previously unrecognized targets, six of which have been selected for development within IMIDomics’ active drug pipeline. To learn more about IMIDomics, please visit www.imidomics.com.